Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

Completed · Phase 3 · Has a placebo group

Conditions studied: Macular Degeneration

In brief

The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months (AA 15 mg, AA 30 mg) in patients with exudative age-related macular degeneration (AMD).

Key facts

Study ID

NCT00299507

Run by

Alcon Research

People needed

240

Starts

2005-03-01

Expected to finish

2008-04-01

Last updated by the study team

2012-11-28

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of exudative AMD and a primary or recurrent (after laser photocoagulation) subfoveal choroidal neovascularization (CNV) lesion.
• Other protocol-defined inclusion criteria may apply.

You may not qualify if…

• Less than 50 years of age.
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Alcon Study Sites — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.